Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Ascendis Pharma A/S ADR (NASDAQ: ASND) closed at $202.99 in the last session, down -2.76% from day before closing price of $208.75. In other words, the price has decreased by -$2.76 from its previous closing price. On the day, 0.89 million shares were traded. ASND stock price reached its highest trading level at $213.81 during the session, while it also had its lowest trading level at $201.13.
Ratios:
We take a closer look at ASND’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.73 and its Current Ratio is at 1.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Peer Perform rating and assigned the stock a target price of $255.
On October 17, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $271.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when JENSEN MICHAEL WOLFF bought 10,000 shares for $208.10 per share.
Jan Moller Mikkelsen bought 100,000 shares of ASND for $21,085,000 on Dec 02 ’25. On Dec 02 ’25, another insider, SPROGOE KENNETT, who serves as the Officer of the company, bought 10,000 shares for $209.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASND now has a Market Capitalization of 12402315264 and an Enterprise Value of 12676872192. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.21. Its current Enterprise Value per Revenue stands at 19.607 whereas that against EBITDA is -94.81.
Stock Price History:
The Beta on a monthly basis for ASND is 0.43, which has changed by 0.5143987 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, ASND has reached a high of $229.94, while it has fallen to a 52-week low of $118.03. The 50-Day Moving Average of the stock is -1.96%, while the 200-Day Moving Average is calculated to be 9.31%.
Shares Statistics:
According to the various share statistics, ASND traded on average about 580.13K shares per day over the past 3-months and 452410 shares per day over the past 10 days. A total of 61.10M shares are outstanding, with a floating share count of 60.47M. Insiders hold about 1.03% of the company’s shares, while institutions hold 104.71% stake in the company. Shares short for ASND as of 1765756800 were 3388247 with a Short Ratio of 5.84, compared to 1763078400 on 2987645. Therefore, it implies a Short% of Shares Outstanding of 3388247 and a Short% of Float of 6.65.
Earnings Estimates
Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is $0.44, with high estimates of $1.07 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$1.78 and -$5.83 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is $3.5, with 13.0 analysts recommending between $6.64 and $1.24.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $245.69M. It ranges from a high estimate of $257.9M to a low estimate of $225.58M. As of. The current estimate, Ascendis Pharma A/S ADR’s year-ago sales were $173.92MFor the next quarter, 11 analysts are estimating revenue of $278.38M. There is a high estimate of $304M for the next quarter, whereas the lowest estimate is $239.04M.
A total of 13 analysts have provided revenue estimates for ASND’s current fiscal year. The highest revenue estimate was $730.6M, while the lowest revenue estimate was $688M, resulting in an average revenue estimate of $714.91M. In the same quarter a year ago, actual revenue was $363.64MBased on 12 analysts’ estimates, the company’s revenue will be $1.3B in the next fiscal year. The high estimate is $1.47B and the low estimate is $1.12B.
